The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$768,988 Vol.
31 mar 2026
30 de junio
1%
31 de diciembre
26%
$768,988 Vol.
30 de junio
$341,889 Vol.
1%
31 de diciembre
$162,217 Vol.
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado abierto: Feb 7, 2026, 5:04 PM ET
Volumen
$768,988Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$768,988Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes